(2S,5S)-2-amino-6-[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]-5-(methylamino)hexanoic acid | 1403482-34-7

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 5'-脱氧核糖核苷
• 英文名称: (2S,5S)-2-amino-6-[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]-5-(methylamino)hexanoic acid
• CAS: 1403482-34-7
• 化学式: C₁₆H₂₅N₇O₅
• 分子量: 395.418
• InChiKey: FZUBRLYJYDVECB-TVDBPQCTSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -3.8
• 重原子数：
  28
• 可旋转键数：
  8
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  195
• 氢给体数：
  6
• 氢受体数：
  11

反应信息

• 作为产物：
  描述：

  在 palladium 10% on activated carbon 、 氢气 、 一水合肼 、 溶剂黄146 作用下， 以 乙醇 、 水 为溶剂， 反应 20.0h， 生成 (2S,5S)-2-amino-6-[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]-5-(methylamino)hexanoic acid
  参考文献：
  名称：

  [EN] METHYLTRANSFERASE INHIBITORS FOR TREATING CANCER
  [FR] INHIBITEURS DE MÉTHYLTRANSFÉRASE POUR TRAITER LE CANCER

  摘要：

  揭示了具有甲基转移酶抑制活性的化合物。这些化合物是氨基酸、酯和酰胺，具有基于腺苷或去氮腺苷的共同核心，并且在治疗与不适当的甲基转移酶活性相关的癌症和类似疾病中非常有用。

  公开号：

  WO2013063417A1

文献信息

• Sinefungin Derivatives as Inhibitors and Structure Probes of Protein Lysine Methyltransferase SETD2
  作者：Weihong Zheng、Glorymar Ibáñez、Hong Wu、Gil Blum、Hong Zeng、Aiping Dong、Fengling Li、Taraneh Hajian、Abdellah Allali-Hassani、Maria F. Amaya、Alena Siarheyeva、Wenyu Yu、Peter J. Brown、Matthieu Schapira、Masoud Vedadi、Jinrong Min、Minkui Luo

  DOI：10.1021/ja307060p

  日期：2012.10.31

  Epigenetic regulation is involved in numerous physiological and pathogenic processes. Among the key regulators that orchestrate epigenetic signaling are over 50 human protein lysine methyltransferases (PKMTs). Interrogation of the functions of individual PKMTs can be facilitated by target-specific PKMT inhibitors. Given the emerging need for such small molecules, we envisioned an approach to identify target-specific methyltransferase inhibitors by screening privileged small-molecule scaffolds against diverse methyltransferases. In this work, we demonstrated the feasibility of such an approach by identifying the inhibitors of SETD2. N-propyl sinefungin (Pr-SNF) was shown to interact preferentially with SETD2 by matching the distinct transition-state features of SETD2's catalytically active conformer. With Pr-SNF as a structure probe, we further revealed the dual roles of SETD2's post-SET loop in regulating substrate access through a distinct topological reconfiguration. Privileged sinefungin scaffolds are expected to have broad use as structure and chemical probes of methyltransferases.
• [EN] METHYLTRANSFERASE INHIBITORS FOR TREATING CANCER<br/>[FR] INHIBITEURS DE MÉTHYLTRANSFÉRASE POUR TRAITER LE CANCER
  申请人：SLOAN KETTERING INST CANCER

  公开号：WO2013063417A1

  公开（公告）日：2013-05-02

  Compounds having methyltransferase inhibitory activity are disclosed. The compounds are amino acids, esters and amides having a common core based on adenosine or deazaadenosine and are useful in the treatment of cancer and similar diseases associated with inappropriate methyltransferase activity.

  揭示了具有甲基转移酶抑制活性的化合物。这些化合物是氨基酸、酯和酰胺，具有基于腺苷或去氮腺苷的共同核心，并且在治疗与不适当的甲基转移酶活性相关的癌症和类似疾病中非常有用。